Login Register Cart 0
Generic placeholder image

Current Chinese Science

Editor-in-Chief

ISSN (Print): 2210-2981
ISSN (Online): 2210-2914

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article Section: Oncology

Current Status of Imaging Diagnosis and Treatment of Subcentimeter Hepatocellular Carcinoma

Author(s): Peng Huang, Yuyao Xiao, Changwu Zhou, Fei Wu, Chun Yang* and Mengsu Zeng*

Volume 3, Issue 6, 2023

Published on: 02 May, 2023

Page: [408 - 419] Pages: 12

DOI: 10.2174/2210298103666230410104223

Price: $65

Abstract

Significant advances in liver imaging technology have facilitated the early detection of subcentimeter hepatocellular carcinoma (HCC). Contrast-enhanced ultrasound, computed tomography, and magnetic resonance imaging (MRI) can be used to diagnose subcentimeter HCC based on the typical imaging features of HCC. Ancillary imaging features such as T2 weightedimaging mild-moderate hyperintensity, restricted diffusion, and hepatobiliary phase hypointensity may improve the diagnostic accuracy of gadoxetic acid-enhanced MRI for subcentimeter HCC. More information is needed to choose between immediate treatment or watchful waiting in subcentimeter HCC. Surgical resection, ablation, and transarterial chemoembolization are effective and safe methods for the management of subcentimeter HCC.

« Previous Next »
Graphical Abstract

[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Zhou, J.; Sun, H.C.; Wang, Z.; Cong, W.M.; Wang, J.H.; Zeng, M.S.; Yang, J.M.; Bie, P.; Liu, L.X.; Wen, T.F.; Han, G.H.; Wang, M.Q.; Liu, R.B.; Lu, L.G.; Ren, Z.G.; Chen, M.S.; Zeng, Z.C.; Liang, P.; Liang, C.H.; Chen, M.; Yan, F.H.; Wang, W.P.; Ji, Y.; Cheng, W.W.; Dai, C.L.; Jia, W.D.; Li, Y.M.; Li, Y.X.; Liang, J.; Liu, T.S.; Lv, G.Y.; Mao, Y.L.; Ren, W.X.; Shi, H.C.; Wang, W.T.; Wang, X.Y.; Xing, B.C.; Xu, J.M.; Yang, J.Y.; Yang, Y.F.; Ye, S.L.; Yin, Z.Y.; Zhang, B.H.; Zhang, S.J.; Zhou, W.P.; Zhu, J.Y.; Liu, R.; Shi, Y.H.; Xiao, Y.S.; Dai, Z.; Teng, G.J.; Cai, J.Q.; Wang, W.L.; Dong, J.H.; Li, Q.; Shen, F.; Qin, S.K.; Fan, J. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer, 2018, 7(3), 235-260.
[http://dx.doi.org/10.1159/000488035] [PMID: 30319983]
[3]
Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; Sangro, B.; Singal, A.G.; Vogel, A.; Fuster, J.; Ayuso, C.; Bruix, J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol., 2022, 76(3), 681-693.
[http://dx.doi.org/10.1016/j.jhep.2021.11.018] [PMID: 34801630]
[4]
Kudo, M.; Kawamura, Y.; Hasegawa, K.; Tateishi, R.; Kariyama, K.; Shiina, S.; Toyoda, H.; Imai, Y.; Hiraoka, A.; Ikeda, M.; Izumi, N.; Moriguchi, M.; Ogasawara, S.; Minami, Y.; Ueshima, K.; Murakami, T.; Miyayama, S.; Nakashima, O.; Yano, H.; Sakamoto, M.; Hatano, E.; Shimada, M.; Kokudo, N.; Mochida, S.; Takehara, T. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer, 2021, 10(3), 181-223.
[http://dx.doi.org/10.1159/000514174] [PMID: 34239808]
[5]
Lu, X.Y.; Xi, T.; Lau, W.Y.; Dong, H.; Xian, Z.H.; Yu, H.; Zhu, Z.; Shen, F.; Wu, M.C.; Cong, W.M. Pathobiological features of small hepatocellular carcinoma: Correlation between tumor size and biological behavior. J. Cancer Res. Clin. Oncol., 2011, 137(4), 567-575.
[http://dx.doi.org/10.1007/s00432-010-0909-5] [PMID: 20508947]
[6]
Usta, S.; Kayaalp, C. Tumor diameter for hepatocellular carcinoma: Why should size matter? J. Gastrointest. Cancer, 2020, 51(4), 1114-1117.
[http://dx.doi.org/10.1007/s12029-020-00483-z] [PMID: 32851543]
[7]
Cong, W.M.; Wu, M.C. Small hepatocellular carcinoma: Current and future approaches. Hepatol. Int., 2013, 7(3), 805-812.
[http://dx.doi.org/10.1007/s12072-013-9454-z] [PMID: 26201917]
[8]
Santi, V.; Trevisani, F.; Gramenzi, A.; Grignaschi, A.; Mirici-Cappa, F.; Poggio, P.D.; Nolfo, M.A.D.; Benvegnù, L.; Farinati, F.; Zoli, M.; Giannini, E.G.; Borzio, F.; Caturelli, E.; Chiaramonte, M.; Bernardi, M. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J. Hepatol., 2010, 53(2), 291-297.
[http://dx.doi.org/10.1016/j.jhep.2010.03.010] [PMID: 20483497]
[9]
International Consensus Group for Hepatocellular Neoplasia The Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology, 2009, 49(2), 658-664.
[http://dx.doi.org/10.1002/hep.22709] [PMID: 19177576]
[10]
Yu, M.H.; Kim, J.H.; Yoon, J.H.; Kim, H.C.; Chung, J.W.; Han, J.K.; Choi, B.I. Small (≤1-cm) hepatocellular carcinoma: Diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology, 2014, 271(3), 748-760.
[http://dx.doi.org/10.1148/radiol.14131996] [PMID: 24588677]
[11]
Choi, J.Y.; Lee, J.M.; Sirlin, C.B. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: Key pathologic and imaging aspects. Radiology, 2014, 272(3), 635-654.
[http://dx.doi.org/10.1148/radiol.14132361] [PMID: 25153274]
[12]
Kojiro, M. Focus on dysplastic nodules and early hepatocellular carcinoma: An Eastern point of view. Liver Transpl., 2004, 10(S2), S3-S8.
[http://dx.doi.org/10.1002/lt.20042] [PMID: 14762831]
[13]
Tomizawa, M.; Kondo, F.; Kondo, Y. Growth patterns and interstitial invasion of small hepatocellular carcinoma. Pathol. Int., 1995, 45(5), 352-358.
[http://dx.doi.org/10.1111/j.1440-1827.1995.tb03468.x] [PMID: 7647931]
[14]
Cerny, M.; Bergeron, C.; Billiard, J.S.; Murphy-Lavallée, J.; Olivié, D.; Bérubé, J.; Fan, B.; Castel, H.; Turcotte, S.; Perreault, P.; Chagnon, M.; Tang, A. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: Performance of major and ancillary features. Radiology, 2018, 288(1), 118-128.
[http://dx.doi.org/10.1148/radiol.2018171678] [PMID: 29634435]
[15]
Roberts, L.R.; Sirlin, C.B.; Zaiem, F.; Almasri, J.; Prokop, L.J.; Heimbach, J.K.; Murad, M.H.; Mohammed, K. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis. Hepatology, 2018, 67(1), 401-421.
[http://dx.doi.org/10.1002/hep.29487] [PMID: 28859233]
[16]
Chernyak, V.; Fowler, K.J.; Kamaya, A.; Kielar, A.Z.; Elsayes, K.M.; Bashir, M.R.; Kono, Y.; Do, R.K.; Mitchell, D.G.; Singal, A.G.; Tang, A.; Sirlin, C.B. Liver imaging reporting and data system (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology, 2018, 289(3), 816-830.
[http://dx.doi.org/10.1148/radiol.2018181494] [PMID: 30251931]
[17]
Kim, T.H.; Kim, S.Y.; Tang, A.; Lee, J.M. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin. Mol. Hepatol., 2019, 25(3), 245-263.
[http://dx.doi.org/10.3350/cmh.2018.0090] [PMID: 30759967]
[18]
Xie, D.Y.; Ren, Z.G.; Zhou, J.; Fan, J.; Gao, Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: Updates and insights. Hepatobiliary Surg. Nutr., 2020, 9(4), 452-463.
[http://dx.doi.org/10.21037/hbsn-20-480] [PMID: 32832496]
[19]
Omata, M.; Cheng, A.L.; Kokudo, N.; Kudo, M.; Lee, J.M.; Jia, J.; Tateishi, R.; Han, K.H.; Chawla, Y.K.; Shiina, S.; Jafri, W.; Payawal, D.A.; Ohki, T.; Ogasawara, S.; Chen, P.J.; Lesmana, C.R.A.; Lesmana, L.A.; Gani, R.A.; Obi, S.; Dokmeci, A.K.; Sarin, S.K. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol. Int., 2017, 11(4), 317-370.
[http://dx.doi.org/10.1007/s12072-017-9799-9] [PMID: 28620797]
[20]
Korean Liver Cancer Association,. K.L.C.A.; National Cancer Center, N.C.C. 2018 Korean liver cancer association–national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver, 2019, 13(3), 227-299.
[http://dx.doi.org/10.5009/gnl19024] [PMID: 31060120]
[21]
Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J-L.; Schirmacher, P.; Vilgrain, V. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 2018, 69(1), 182-236.
[http://dx.doi.org/10.1016/j.jhep.2018.03.019] [PMID: 29628281]
[22]
Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology, 2018, 68(2), 723-750.
[http://dx.doi.org/10.1002/hep.29913] [PMID: 29624699]
[23]
Kudo, M.; Izumi, N.; Kokudo, N.; Matsui, O.; Sakamoto, M.; Nakashima, O.; Kojiro, M.; Makuuchi, M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis., 2011, 29(3), 339-364.
[http://dx.doi.org/10.1159/000327577] [PMID: 21829027]
[24]
Hwang, S.H.; Hong, S.B.; Park, S.; Han, K.; Park, Y.N.; Kim, S.Y.; Park, M.S. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid–enhanced MRI. Eur. Radiol., 2021, 31(4), 2321-2331.
[http://dx.doi.org/10.1007/s00330-020-07329-z] [PMID: 33044650]
[25]
Ham, J.H.; Yu, J.S.; Choi, J.M.; Cho, E.S.; Kim, J.H.; Chung, J.J. Corona enhancement can substitute enhancing capsule in the imaging diagnosis of small (≤ 3 cm) HCCs on gadoxetic acid–enhanced MRI. Eur. Radiol., 2021, 31(11), 8628-8637.
[http://dx.doi.org/10.1007/s00330-021-07911-z] [PMID: 33891153]
[26]
Kang, Y.; Lee, J.M.; Kim, S.H.; Han, J.K.; Choi, B.I. Intrahepatic mass-forming cholangiocarcinoma: Enhancement patterns on gadoxetic acid-enhanced MR images. Radiology, 2012, 264(3), 751-760.
[http://dx.doi.org/10.1148/radiol.12112308] [PMID: 22798225]
[27]
Doo, K.W.; Lee, C.H.; Choi, J.W.; Lee, J.; Kim, K.A.; Park, C.M. “Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am. J. Roentgenol., 2009, 193(6), W490-W496.
[http://dx.doi.org/10.2214/AJR.08.1732] [PMID: 19933623]
[28]
Lee, S.J.; Kim, S.Y.; Kim, K.W.; Kim, J.H.; Kim, H.J.; Lee, M.G.; Yu, E.S. Hepatic angiomyolipoma versus hepatocellular carcinoma in the noncirrhotic liver on gadoxetic acid–enhanced MRI: A diagnostic challenge. AJR Am. J. Roentgenol., 2016, 207(3), 562-570.
[http://dx.doi.org/10.2214/AJR.15.15602] [PMID: 27248975]
[29]
Kim, Y.K.; Kim, C.S.; Moon, W.S.; Cho, B.H.; Lee, S.Y.; Lee, J.M. MRI findings of focal eosinophilic liver diseases. AJR Am. J. Roentgenol., 2005, 184(5), 1541-1548.
[http://dx.doi.org/10.2214/ajr.184.5.01841541] [PMID: 15855113]
[30]
Tang, A.; Cruite, I.; Mitchell, D.G.; Sirlin, C.B. Hepatocellular carcinoma imaging systems: Why they exist, how they have evolved, and how they differ. Abdom. Radiol., 2018, 43(1), 3-12.
[http://dx.doi.org/10.1007/s00261-017-1292-3] [PMID: 28840293]
[31]
Wald, C.; Russo, M.W.; Heimbach, J.K.; Hussain, H.K.; Pomfret, E.A.; Bruix, J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology, 2013, 266(2), 376-382.
[http://dx.doi.org/10.1148/radiol.12121698] [PMID: 23362092]
[32]
Choi, J.Y.; Lee, J.M.; Sirlin, C.B. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology, 2014, 273(1), 30-50.
[http://dx.doi.org/10.1148/radiol.14132362] [PMID: 25247563]
[33]
Kitao, A.; Matsui, O.; Yoneda, N.; Kozaka, K.; Kobayashi, S.; Koda, W.; Inoue, D.; Ogi, T.; Yoshida, K.; Gabata, T. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: Molecular and genetic background. Eur. Radiol., 2020, 30(6), 3438-3447.
[http://dx.doi.org/10.1007/s00330-020-06687-y] [PMID: 32064560]
[34]
Choi, M.H.; Choi, J.I.; Lee, Y.J.; Park, M.Y.; Rha, S.E.; Lall, C. MRI of small hepatocellular carcinoma: Typical features are less frequent below a size cutoff of 1.5 cm. AJR Am. J. Roentgenol., 2017, 208(3), 544-551.
[http://dx.doi.org/10.2214/AJR.16.16414] [PMID: 28026208]
[35]
Luca, A.; Caruso, S.; Milazzo, M.; Mamone, G.; Marrone, G.; Miraglia, R.; Maruzzelli, L.; Carollo, V.; Minervini, M.I.; Vizzini, G.; Grutttadauria, S.; Gridelli, B. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: Prevalence of radiological vascular patterns and histological correlation with liver explants. Eur. Radiol., 2010, 20(4), 898-907.
[http://dx.doi.org/10.1007/s00330-009-1622-0] [PMID: 19802612]
[36]
Okamoto, D.; Yoshimitsu, K.; Nishie, A.; Tajima, T.; Asayama, Y.; Ishigami, K.; Hirakawa, M.; Ushijima, Y.; Kakihara, D.; Nakayama, T.; Nishihara, Y.; Aishima, S.; Taketomi, A.; Kishimoto, J.; Honda, H. Enhancement pattern analysis of hypervascular hepatocellular carcinoma on dynamic MR imaging with histopathological correlation: Validity of portal phase imaging for predicting tumor grade. Eur. J. Radiol., 2012, 81(6), 1116-1121.
[http://dx.doi.org/10.1016/j.ejrad.2011.02.056] [PMID: 21420813]
[37]
Joo, I.; Lee, J.M.; Lee, D.H.; Jeon, J.H.; Han, J.K.; Choi, B.I. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur. Radiol., 2015, 25(10), 2859-2868.
[http://dx.doi.org/10.1007/s00330-015-3686-3] [PMID: 25773941]
[38]
Pan, J.; Tao, Y.; Chi, X.; Yang, L.; Zhao, Y.; Chen, F. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: A systematic review and meta-analysis. Eur. Radiol., 2022, 32(8), 5134-5143.
[http://dx.doi.org/10.1007/s00330-022-08665-y] [PMID: 35267090]
[39]
Park, M.J.; Kim, Y.K.; Lee, M.W.; Lee, W.J.; Kim, Y.S.; Kim, S.H.; Choi, D.; Rhim, H. Small hepatocellular carcinomas: Improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology, 2012, 264(3), 761-770.
[http://dx.doi.org/10.1148/radiol.12112517] [PMID: 22843769]
[40]
Kim, J.E.; Kim, S.H.; Lee, S.J.; Rhim, H. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: Characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am. J. Roentgenol., 2011, 196(6), W758-W765.
[http://dx.doi.org/10.2214/AJR.10.4394] [PMID: 21606265]
[41]
Park, C.J.; An, C.; Park, S.; Choi, J.Y.; Kim, M.J. Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC. Eur. Radiol., 2018, 28(4), 1476-1484.
[http://dx.doi.org/10.1007/s00330-017-5088-1] [PMID: 29063251]
[42]
Song, K.D.; Kim, S.H.; Lim, H.K.; Jung, S.H.; Sohn, I.; Kim, H.S. Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: Natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging. Eur. Radiol., 2015, 25(9), 2789-2796.
[http://dx.doi.org/10.1007/s00330-015-3680-9] [PMID: 25735515]
[43]
Jang, K.M.; Kim, S.H.; Kim, Y.K.; Choi, D. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiol., 2015, 56(5), 526-535.
[http://dx.doi.org/10.1177/0284185114534652] [PMID: 24838304]
[44]
Roayaie, S.; Obeidat, K.; Sposito, C.; Mariani, L.; Bhoori, S.; Pellegrinelli, A.; Labow, D.; Llovet, J.M.; Schwartz, M.; Mazzaferro, V. Resection of hepatocellular cancer ≤2 cm: Results from two Western centers. Hepatology, 2013, 57(4), 1426-1435.
[http://dx.doi.org/10.1002/hep.25832] [PMID: 22576353]
[45]
Feng, L.H.; Sun, H.C.; Zhu, X.D.; Liu, X.F.; Zhang, S.Z.; Li, X.L.; Li, Y.; Tang, Z.Y. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur. J. Surg. Oncol., 2021, 47(3), 681-689.
[http://dx.doi.org/10.1016/j.ejso.2020.10.039] [PMID: 33189491]
[46]
Wang, W.; Yang, C.; Zhu, K.; Yang, L.; Ding, Y.; Luo, R.; Zhu, S.; Chen, C.; Sun, W.; Zeng, M.; Rao, S.X. Recurrence after curative resection of hepatitis b virus–related hepatocellular carcinoma: Diagnostic algorithms on gadoxetic acid–enhanced magnetic resonance imaging. Liver Transpl., 2020, 26(6), 751-763.
[http://dx.doi.org/10.1002/lt.25713] [PMID: 31901208]
[47]
Dong, Y.; Teufel, A.; Wang, W.P.; Dietrich, C.F. Current opinion about hepatocellular carcinoma <10 mm. Digestion, 2021, 102(3), 335-341.
[http://dx.doi.org/10.1159/000507923] [PMID: 32516767]
[48]
Laghi, F.; Catalano, O.; Maresca, M.; Sandomenico, F.; Siani, A. Indeterminate, subcentimetric focal liver lesions in cancer patients: Additional role of contrast-enhanced ultrasound. Ultraschall Med., 2010, 31(3), 283-288.
[http://dx.doi.org/10.1055/s-0029-1245383] [PMID: 20517816]
[49]
Strobel, D.; Bernatik, T.; Blank, W.; Schuler, A.; Greis, C.; Dietrich, C.F.; Seitz, K. Diagnostic accuracy of CEUS in the differential diagnosis of small (≤ 20 mm) and subcentimetric (≤ 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall Med., 2011, 32(6), 593-597.
[http://dx.doi.org/10.1055/s-0031-1271114] [PMID: 22161556]
[50]
Kudo, M.; Matsui, O.; Izumi, N.; Iijima, H.; Kadoya, M.; Imai, Y. Surveillance and diagnostic algorithm for hepatocellular carcinoma pro-posed by the Liver Cancer Study Group of Japan: 2014 update. Oncology, 2014, 87(S1), 7-21.
[http://dx.doi.org/10.1159/000368141] [PMID: 25427729]
[51]
Numata, K.; Fukuda, H.; Nihonmatsu, H.; Kondo, M.; Nozaki, A.; Chuma, M.; Morimoto, M.; Oshima, T.; Okada, M.; Murakami, T.; Takebayashi, S.; Maeda, S.; Inayama, Y.; Nakano, M.; Tanaka, K. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. Abdom. Imaging, 2015, 40(7), 2372-2383.
[http://dx.doi.org/10.1007/s00261-015-0489-6] [PMID: 26099473]
[52]
Choi, B.I.; Lee, J.M.; Kim, T.K.; Burgio, M.D.; Vilgrain, V. Diagnosing borderline hepatic nodules in hepatocarcinogenesis: Imaging per-formance. AJR Am. J. Roentgenol., 2015, 205(1), 10-21.
[http://dx.doi.org/10.2214/AJR.14.12655] [PMID: 26102378]
[53]
Sugimoto, K.; Moriyasu, F.; Shiraishi, J.; Saito, K.; Taira, J.; Saguchi, T.; Imai, Y. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur. Radiol., 2012, 22(6), 1205-1213.
[http://dx.doi.org/10.1007/s00330-011-2372-3] [PMID: 22270142]
[54]
Heimbach, J.K.; Kulik, L.M.; Finn, R.S.; Sirlin, C.B.; Abecassis, M.M.; Roberts, L.R.; Zhu, A.X.; Murad, M.H.; Marrero, J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018, 67(1), 358-380.
[http://dx.doi.org/10.1002/hep.29086] [PMID: 28130846]
[55]
Dietrich, C.F. Liver tumor characterization--comments and illustrations regarding guidelines. Ultraschall Med., 2012, 33(S1), S22-S30.
[http://dx.doi.org/10.1055/s-0032-1312892] [PMID: 22723025]
[56]
Maruyama, H.; Takahashi, M.; Ishibashi, H.; Yoshikawa, M.; Yokosuka, O. Contrast-enhanced ultrasound for characterisation of hepatic lesions appearing non-hypervascular on CT in chronic liver diseases. Br. J. Radiol., 2012, 85(1012), 351-357.
[http://dx.doi.org/10.1259/bjr/20440141] [PMID: 21224305]
[57]
Park, M.J.; Kim, Y.; Lee, W.J.; Lim, H.K.; Rhim, H.; Lee, J. Outcomes of follow-up CT for small (5–10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population. Eur. Radiol., 2010, 20(10), 2397-2404.
[http://dx.doi.org/10.1007/s00330-010-1810-y] [PMID: 20559837]
[58]
Fuji, T.; Nakamura, Y.; Fukumoto, W.; Kajiwara, K.; Chosa, K.; Tani, C.; Matsubara, Y.; Terada, H.; Honda, Y.; Arihiro, K.; Iida, M.; Baba, Y.; Awai, K. Clinical indication for computed tomography during hepatic arteriography (CTHA) in addition to dynamic CT studies to identify hypervascularity of hepatocellular carcinoma. Cardiovasc. Intervent. Radiol., 2018, 41(4), 618-627.
[http://dx.doi.org/10.1007/s00270-017-1832-9] [PMID: 29101449]
[59]
Pugacheva, O.; Matsui, O.; Kozaka, K.; Minami, T.; Ryu, Y.; Koda, W.; Kobayashi, S.; Gabata, T. Detection of small hypervascular hepatocellular carcinomas by EASL criteria: Comparison with double-phase CT during hepatic arteriography. Eur. J. Radiol., 2011, 80(3), e201-e206.
[http://dx.doi.org/10.1016/j.ejrad.2010.08.036] [PMID: 20855175]
[60]
Meyer, B.C.; Frericks, B.B.; Voges, M.; Borchert, M.; Martus, P.; Justiz, J.; Wolf, K.J.; Wacker, F.K. Visualization of hypervascular liver lesions During TACE: Comparison of angiographic C-arm CT and MDCT. AJR Am. J. Roentgenol., 2008, 190(4), W263-W269.
[http://dx.doi.org/10.2214/AJR.07.2695] [PMID: 18356419]
[61]
Miyayama, S.; Yamashiro, M.; Okuda, M.; Yoshie, Y.; Nakashima, Y.; Ikeno, H.; Orito, N.; Matsui, O. Detection of corona enhancement of hypervascular hepatocellular carcinoma by C-arm dual-phase cone-beam CT during hepatic arteriography. Cardiovasc. Intervent. Radiol., 2011, 34(1), 81-86.
[http://dx.doi.org/10.1007/s00270-010-9835-9] [PMID: 20333382]
[62]
Pung, L.; Ahmad, M.; Mueller, K.; Rosenberg, J.; Stave, C.; Hwang, G.L.; Shah, R.; Kothary, N. The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma: A systematic review and meta-analysis. J. Vasc. Interv. Radiol., 2017, 28(3), 334-341.
[http://dx.doi.org/10.1016/j.jvir.2016.11.037] [PMID: 28109724]
[63]
Yu, M.H.; Kim, J.H.; Yoon, J.H.; Kim, H.C.; Chung, J.W.; Han, J.K.; Choi, B.I. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: Diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI. AJR Am. J. Roentgenol., 2013, 201(3), 675-683.
[http://dx.doi.org/10.2214/AJR.12.10445] [PMID: 23971463]
[64]
Park, C.M.; Cha, S.H.; Kim, D.H.; Choi, J.A.; Cha, I.H.; Kim, Y.H.; Chung, K.B.; Suh, W.H. Hepatic arterioportal shunts not directly related to hepatocellular carcinoma: findings on CT during hepatic arteriography, CT arterial portography and dual phase spiral CT. Clin. Radiol., 2000, 55(6), 465-470.
[http://dx.doi.org/10.1053/crad.2000.0477] [PMID: 10873693]
[65]
Sun, X.; Hu, D.; Zhang, Y.; Lyu, N.; Xu, L.; Chen, Q.; Lai, J.; Chen, M.; Zhao, M. Can immediately treating subcentimeter hepatocellular carcinoma improve the survival of patients? J. Hepatocell. Carcinoma, 2020, 7, 377-384.
[http://dx.doi.org/10.2147/JHC.S287641] [PMID: 33365285]
[66]
Woo, J.H.; Song, K.D.; Kim, S.H. Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Outcomes of early treatment and watchful waiting. Eur. Radiol., 2017, 27(10), 4406-4414.
[http://dx.doi.org/10.1007/s00330-017-4818-8] [PMID: 28386720]
[67]
Schlageter, M.; Terracciano, L.M.; D’Angelo, S.; Sorrentino, P. Histopathology of hepatocellular carcinoma. World J. Gastroenterol., 2014, 20(43), 15955-15964.
[http://dx.doi.org/10.3748/wjg.v20.i43.15955] [PMID: 25473149]
[68]
Xu, X.L.; Liu, X.D.; Liang, M.; Luo, B.M. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: Systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology, 2018, 287(2), 461-472.
[http://dx.doi.org/10.1148/radiol.2017162756] [PMID: 29135366]
[69]
Wen, T.; Jin, C.; Facciorusso, A.; Donadon, M.; Han, H.S.; Mao, Y.; Dai, C.; Cheng, S.; Zhang, B.; Peng, B.; Du, S.; Jia, C.; Xu, F.; Shi, J.; Sun, J.; Zhu, P.; Nara, S.; Millis, J.M. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: An international expert consensus. Hepatobiliary Surg. Nutr., 2018, 7(5), 353-371.
[http://dx.doi.org/10.21037/hbsn.2018.08.01] [PMID: 30498711]
[70]
Rossi, G.; Tarasconi, A.; Baiocchi, G. De’ Angelis, G.L.; Gaiani, F.; Di Mario, F.; Catena, F.; Dalla Valle, R. Fluorescence guided surgery in liver tumors: Applications and advantages. Acta. Biomed., 2018, 89(9-S), 135-140.
[PMID: 30561406]
[71]
Chen, H.; Cheng, H.; Dai, Q.; Cheng, Y.; Zhang, Y.; Li, D.; Sun, Y.; Mao, J.; Ren, K.; Chu, C.; Liu, G. A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment. J. Control. Release, 2020, 323, 635-643.
[http://dx.doi.org/10.1016/j.jconrel.2020.04.021] [PMID: 32302761]
[72]
Donadon, M.; Costa, G.; Torzilli, G. State of the art of intraoperative ultrasound in liver surgery: Current use for staging and resection guidance. Ultraschall. Med., 2014, 35(6), 500-514.
[http://dx.doi.org/10.1055/s-0034-1385515] [PMID: 25474100]
[73]
Weinstein, J.L.; Ahmed, M. Percutaneous ablation for hepatocellular carcinoma. AJR Am. J. Roentgenol., 2018, 210(6), 1368-1375.
[http://dx.doi.org/10.2214/AJR.17.18695] [PMID: 29702018]
[74]
Vietti Violi, N.; Duran, R.; Guiu, B.; Cercueil, J.P.; Aubé, C.; Digklia, A.; Pache, I.; Deltenre, P.; Knebel, J.F.; Denys, A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: A randomised controlled phase 2 trial. Lancet Gastroenterol. Hepatol., 2018, 3(5), 317-325.
[http://dx.doi.org/10.1016/S2468-1253(18)30029-3] [PMID: 29503247]
[75]
Abdelaziz, A.; Elbaz, T.; Shousha, H.I.; Mahmoud, S.; Ibrahim, M.; Abdelmaksoud, A.; Nabeel, M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: An egyptian multidisciplinary clinic experience. Surg. Endosc., 2014, 28(12), 3429-3434.
[http://dx.doi.org/10.1007/s00464-014-3617-4] [PMID: 24935203]
[76]
Yu, J.; Yu, X.; Han, Z.; Cheng, Z.; Liu, F.; Zhai, H.; Mu, M.; Liu, Y.; Liang, P. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase III randomised controlled trial. Gut, 2017, 66(6), 1172-1173.
[http://dx.doi.org/10.1136/gutjnl-2016-312629] [PMID: 27884919]
[77]
Pompili, M.; De Matthaeis, N.; Saviano, A.; De Sio, I.; Francica, G.; Brunello, F.; Cantamessa, A.; Giorgio, A.; Scognamiglio, U.; Fornari, F.; Giangregorio, F.; Piscaglia, F.; Gualandi, S.; Caturelli, E.; Roselli, P.; Riccardi, L.; Rapaccini, G.L. Single hepatocellular carcinoma smaller than 2 cm: Are ethanol injection and radiofrequency ablation equally effective? Anticancer Res., 2015, 35(1), 325-332.
[PMID: 25550567]
[78]
Zhang, T.; Zeng, Y.; Huang, J.; Liao, M.; Wu, H. Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: A single-center experience. J. Surg. Res., 2014, 191(2), 370-378.
[http://dx.doi.org/10.1016/j.jss.2014.03.048] [PMID: 24766727]
[79]
Okamoto, E.; Sato, S.; Sanchez-Siles, A.A.; Ishine, J.; Miyake, T.; Amano, Y.; Kinoshita, Y. Evaluation of virtual CT sonography for enhanced detection of small hepatic nodules: A prospective pilot study. AJR Am. J. Roentgenol., 2010, 194(5), 1272-1278.
[http://dx.doi.org/10.2214/AJR.08.2294] [PMID: 20410414]
[80]
Song, K.D.; Lee, M.W.; Rhim, H.; Kang, T.W.; Cha, D.I.; Sinn, D.H.; Lim, H.K. Percutaneous US/MRI fusion–guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: Technical feasibility and therapeutic outcomes. Radiology, 2018, 288(3), 878-886.
[http://dx.doi.org/10.1148/radiol.2018172743] [PMID: 29916771]
[81]
Miyayama, S. Ultraselective conventional transarterial chemoembolization: When and how? Clin. Mol. Hepatol., 2019, 25(4), 344-353.
[http://dx.doi.org/10.3350/cmh.2019.0016] [PMID: 31022779]
[82]
Miyayama, S.; Yamashiro, M.; Ikeda, R.; Matsumoto, J.; Takeuchi, K.; Sakuragawa, N.; Ueda, T.; Sanada, T.; Notsumata, K.; Terada, T. Efficacy of superselective conventional transarterial chemoembolization using guidance software for hepatocellular carcinoma within three lesions smaller than 3 cm. Cancers, 2021, 13(24), 6370.
[http://dx.doi.org/10.3390/cancers13246370] [PMID: 34944990]
[83]
Choi, J.W.; Kim, H.C.; Lee, J.H.; Yu, S.J.; Cho, E.J.; Kim, M.U.; Hur, S.; Lee, M.; Jae, H.J.; Chung, J.W. Cone beam CT–guided chemoembolization of probable hepatocellular carcinomas smaller than 1 cm in patients at high risk of hepatocellular carcinoma. J. Vasc. Interv. Radiol., 2017, 28(6), 795-803.e1.
[http://dx.doi.org/10.1016/j.jvir.2017.01.014] [PMID: 28302348]
[84]
Hyun, D.; Cho, S.K.; Shin, S.W.; Park, K.B.; Lee, S.Y.; Park, H.S.; Do, Y.S. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: Long-term out-comes. Acta Radiol., 2018, 59(7), 773-781.
[http://dx.doi.org/10.1177/0284185117735349] [PMID: 29034691]
[85]
Yamakado, K.; Nakatsuka, A.; Takaki, H.; Yokoi, H.; Usui, M.; Sakurai, H.; Isaji, S.; Shiraki, K.; Fuke, H.; Uemoto, S.; Takeda, K. Early-stage hepatocellular carcinoma: Radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology, 2008, 247(1), 260-266.
[http://dx.doi.org/10.1148/radiol.2471070818] [PMID: 18305190]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy